Patient-reported outcomes in immunotherapy for head and neck cancer.
Kedar S KirtaneAasha I HooglandXiaoyin LiYvelise RodriguezKelsey ScheelBrent J SmallLaura B OswaldJameel MuzaffarJulie A KishMarcelo BonomiPriyanka BhatejaNabil F SabaConor E SteuerChristine H ChungHeather S L JimPublished in: Head & neck (2023)
Despite increasing patient-reported toxicity, checkpoint inhibitor monotherapy and combination therapy were associated with similar transient improvements, then worsening, of QOL in patients with HNSCC.